[{"from": "human", "value": "Provide a description of this molecule. [C][C][=C][Branch2][Ring2][Branch1][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=Branch1][=Branch1][=N][C][=C][Ring1][Branch2][N][C][=C][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][O][C][Branch1][C][F][Branch1][C][F][F][N][C][=C][Branch1][#Branch1][C][=C][C][=N][Ring1][=Branch1][C][=C][C][=Branch1][=Branch1][=N][C][=N][Ring1][=Branch1][N][=C][N][Ring1][Branch2]"}, {"from": "gpt", "value": "The molecule is a topically bioavailable small molecule inhibitor of serine/threonine-protein kinase B-raf (BRAF) protein with potential chemoprotective activity. Upon topical administration, BRAF inhibitor LUT014 targets and binds BRAF and, through the paradoxical effect of BRAF inhibition, induces mitogen-activated protein kinase (MAPK) signaling, which leads to the proliferation and migration of healthy human keratinocytes. This decreases dermal toxicities associated with epidermal growth factor (EGFR) inhibitor therapy. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of MAPK/extracellular signal-regulated kinase (ERK) signaling pathways."}]